BEIGF 8-K 2026-11-05
BeOne Medicines Ltd. (BEIGF) 8-K dated 2026-11-05 — accession 0001628280-26-070469.
BeOne Medicines Ltd. (BEIGF) is a biotechnology company listed on US.
BEIGF: BeOne Medicines Announces Third Quarter 2026 Financial Results and Busi…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Income-statement cache for BEIGF is thin on this filing URL. We will not invent exhibit numbers.
Not investment advice. The BEIGF SEC hub lists recent forms. The stock page is the research view.
- Diluted EPS
- $0.26
- Guidance
- guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billi
Why it matters
- guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billi